brain-tumor-therapeutics-market
Published

MAR 2018

Global Brain Tumor Therapeutics Market - Segmented by Type of Cancer and Therapeutics - Growth, Trends and Forecasts (2018 - 2023)

Purchase Report
$4250
Single user license
$4500
Team license
$8750
Corporate license

The global brain tumor therapeutics market has been estimated to reach USD 2.74 billion in 2023. The market is expected to register a CAGR of 11% during the forecast period, 2018 to 2023. North America dominates the market due to increasing technological advancements. Developed healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies are the other impact rendering factors.

Increasing Incidence of Brain Cancer and Focus on Precision Medicine

Increasing incidences of brain cancer have augmented the demand for brain cancer therapeutics across the globe, which is driving the market. In addition, increased focus on precision medicine is also fuelling the global brain tumor therapeutics market.  

Few Brain Cancer-specific Drugs and High Cost of Treatment

Availability of only a few brain cancer-specific drugs and their high cost are acting as restraints for the brain tumor therapeutics market. Nevertheless, various pharmaceutical companies are spending heavily on R&D activities, which can bring more treatment options to the market in future.

North America to Dominate the Market

The brain tumor therapeutics market is segmented by type of treatment and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.

North America dominates the brain tumor therapeutics market due to increasing technological advancements and the rising incidences of brain cancer in the country. Asia-Pacific is also expected to propel the brain tumor therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing geriatric population.

Key Developments in the Market

  • January  2018:  iTeos Therapeutics regained rights to its Phase I brain cancer drug from Pfizer, and plans to continue oncology development.
  • December 2017:  Diffusion Pharmaceuticals (DFFN) launched Phase III trial for Glioblastoma

Major Players: F. Hoffmann-La Roche AG, Merck, Novartis, Immunocellular Therapeutics, NOVOCURE, Delmar Pharmaceuticals Inc., and Moleculin Biotech, among others.

Reasons to Purchase this Report

  • Market analysis for the global brain tumor therapeutics market, with region-specific assessments and competition analysis on both global and regional scales
  • Analyzing various perspectives of the company with the help of Porter’s five forces analysis
  • The treatment type that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares and strategies employed by the major market players
  • 3 months analyst support along with the Market Estimate sheet in excel

Customization of the Report

  • This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs
Purchase Report
$4250
Single user license
$4500
Team license
$8750
Corporate license
Our Clients Include View All

Looking to Customize Report?